Fast Five Quiz: Idiopathic Pulmonary Fibrosis Treatment

Guy W. Soo Hoo, MD, MPH; Zab Mosenifar, MD

Disclosures

May 12, 2022

Antifibrotic agents, namely nintedanib and pirfenidone, are the only medications approved by the US Food and Drug Administration for the treatment of IPF. Although these drugs are not curative, they have been shown to slow the fibrotic changes associated with IPF. Nintedanib, a tyrosine kinase receptor blocker, preserves lung function by slowing fibrogenesis, and also may increase the length of time to a patient's first AE-IPF. Pirfenidone, a pyridone derivative recommended for mild to moderate IPF, slows fibrogenesis by inhibiting collagen formation. The updated American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society IPF guidelines include a conditional recommendation for antifibrotic therapy.

Anticoagulants, antibiotics, and antihypertensives are not used in treatment of IPF.

Learn more about antifibrotic agents in the treatment of IPF.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....